VBWG - Resource Item

Resources

Quick Order
About Create Profile Login
Email: Password:

Slide Lecture Programs
2003 Core Curriculum cash advance cash advance
Impact of vascular biology in treatment of cardiovascular disease Section IV: Antithrombotic interventions in acute coronary syndromes cash advance cash advance
May 28, 2003
Table of Contents - 39 slides
No.	Title
1	CHD-related catheterization cash advance cash advance
2	Global variation in hospital management of ACS cash advance cash advance
3	Antithrombotic and prothrombotic molecules cash advance cash advance
4	Plaque rupture cash advance cash advance
5	Thrombotic pathways cash advance cash advance
6	Platelet activation cash advance cash advance
7	FRISC-II: Sustained benefit of early invasive strategy in UA/NSTEMI cash advance cash advance
8	RITA 3: Evidence supporting early interventional strategy in UA/NSTEMI cash advance cash advance
9	Model of in-stent restenosis cash advance cash advance
10	In-stent restenosis rates cash advance cash advance
11	RAVEL: 1-Year survival free of MI or repeat revascularization cash advance cash advance
12	TAXUS I: Results at 6 and 12 months cash advance cash advance
13	Primary PTCA vs thrombolysis in STEMI cash advance cash advance
14	Major actions of antithrombotic agents cash advance cash advance
15	Direct thrombin inhibitors in PCI: Peak-activated clotting time by dose (CACHET) cash advance cash advance
16	REPLACE-2: Death, MI, urgent revascularization, major bleeding cash advance cash advance
17	Proposed model for optimal use of GP IIb/IIIa inhibitors cash advance cash advance
18	GP IIb/IIIa inhibitors: Benefit related to revascularization strategy cash advance cash advance
19	GP IIb/IIIa inhibitors: Events prevented and number-needed-to-treat by management strategy cash advance cash advance
20	Differing effects of anticoagulants on vWF cash advance cash advance
21	LMWH inhibits factor VIIa generation and prothrombin activation in vivo cash advance cash advance
22	LMWH in PCI: Patients meeting anticoagulant goal at time of procedure cash advance cash advance
23	Timecourse of anticoagulation with LMWH (enoxaparin) cash advance cash advance
24	Evaluation of LMWH in high-risk UA/NSTEMI cash advance cash advance
25	Anticoagulant efficacy in high-risk patients receiving LMWH cash advance cash advance
26	Trials of LMWH plus GP Iib/IIIa inhibitors in PCI cash advance cash advance
27	NRMI 3: LMWH/UFH plus GP Iib/IIIa inhibitors cash advance cash advance
28	INTERACT: LMWH/UFH plus GP Iib/IIIa inhibitor in UA/NSTEMI cash advance cash advance
29	INTERACT: LMWH/UFH plus GP Iib/IIIa inhibitor in non-ST-elevation ACS cash advance cash advance
30	CRUISE: LMWH/UFH plus GP Iib/IIIa inhibitor in PCI cash advance cash advance
31	CRUISE: LMWH/UFH plus GP Iib/IIIa inhibitor in PCI (cont'd) cash advance cash advance
32	Consensus algorithm for use of LMWH in PCI cash advance cash advance
33	Adverse implications of diabetes in patients with ACS cash advance cash advance
34	Adverse impact of diabetes on survival following PCI cash advance cash advance
35	ARTS: CABG vs stenting in patients with and without diabetes cash advance cash advance
36	EPISTENT: GP IIb/IIIa inhibition reduces target vessel revascularization in diabetics undergoing stenting cash advance cash advance
37	1 in 3 NSTEMI patients: Culprit lesion not identified on angiography cash advance cash advance
38	ACC/AHA guidelines for UA/NSTEMI: Revascularization in patients with diabetes cash advance cash advance
39	ACC/AHA guidelines for UA/NSTEMI: Class I recommendations for antithrombotic therapy cash advance cash advance


Home \| Literature Update \| Journal Link \| Resources \| Meeting Highlights \| Members \| About VBWG \| Web Links